The price of Bristol-Myers Squibb Company (NYSE: BMY) closed at 69.46 in the last session, down -0.39% from day before closing price of $69.73. In other words, the price has decreased by $-0.27 from its previous closing price. On the day, 11789780 shares were traded. BMY reached its highest trading level at $70.37 during the session, while it also had its lowest trading level at $69.44.
We take a closer look at BMY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.26. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 1.29 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Berenberg on September 14, 2022, Downgraded its rating to Hold and sets its target price to $76 from $82 previously.
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 15 when Caforio Giovanni sold 50,000 shares for $71.84 per share. The transaction valued at 3,592,000 led to the insider holds 501,104 shares of the business.
Powell Ann sold 25,000 shares of BMY for $1,768,750 on Sep 14. The EVP, Chief Human Resources now owns 50,476 shares after completing the transaction at $70.75 per share. On Sep 13, another insider, Elkins David V, who serves as the EVP, Chief Financial Officer of the company, sold 133,951 shares for $71.30 each. As a result, the insider received 9,551,167 and left with 100,460 shares of the company.
As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.08, and their Forward P/E ratio for the next fiscal year is 8.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.16 while its Price-to-Book (P/B) ratio in mrq is 4.55.
Stock Price History:
Over the past 52 weeks, BMY has reached a high of $80.59, while it has fallen to a 52-week low of $53.22. The 50-Day Moving Average of the stock is 72.41, while the 200-Day Moving Average is calculated to be 70.82.
According to the various share statistics, BMY traded on average about 9.83M shares per day over the past 3-months and 11.54M shares per day over the past 10 days. A total of 2.14B shares are outstanding, with a floating share count of 2.13B. Insiders hold about 0.07% of the company’s shares, while institutions hold 79.80% stake in the company. Shares short for BMY as of Jul 14, 2022 were 27.33M with a Short Ratio of 2.31, compared to 34.46M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.28% and a Short% of Float of 1.28%.
Dividends & Splits
The forward annual dividend rate for BMY is 2.16, which was 1.88 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 2.70%, it implies a Forward Annual Dividend Yield of 2.93%. The stock’s 5-year Average Dividend Yield is 2.94. The current Payout Ratio is 67.90% for BMY, which recently paid a dividend on Oct 31, 2022 with an ex-dividend date of Jun 29, 2022. Stock splits for the company last occurred on Aug 06, 2001 when the company split stock in a 1000000:951777 ratio.
The company has 17 analysts who recommend its stock at the moment. On average, analysts expect EPS of $1.85 for the current quarter, with a high estimate of $1.96 and a low estimate of $1.76, while EPS last year was $2. The consensus estimate for the next quarter is $1.76, with high estimates of $1.92 and low estimates of $1.6.
Analysts are recommending an EPS of between $7.65 and $7.35 for the fiscal current year, implying an average EPS of $7.51. EPS for the following year is $8.02, with 21 analysts recommending between $8.61 and $7.55.
According to 13 analysts, the current quarter’s revenue is expected to be $11.19B. It ranges from a high estimate of $11.63B to a low estimate of $10.81B. As of the current estimate, Bristol-Myers Squibb Company’s year-ago sales were $11.58B, an estimated decrease of -3.40% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $11.44B, a decrease of -4.60% less than the figure of $-3.40% in the same quarter last year. There is a high estimate of $11.86B for the next quarter, whereas the lowest estimate is $11.18B.
A total of 21 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $46.78B, while the lowest revenue estimate was $45.56B, resulting in an average revenue estimate of $46.12B. In the same quarter a year ago, actual revenue was $46.38B, down -0.60% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $47.87B in the next fiscal year. The high estimate is $49.67B and the low estimate is $46.59B. The average revenue growth estimate for next year is up 3.80% from the average revenue estimate for this year.